VIDEO: Presentation focuses on RPE cells in AMD

ByCory Perla

Fact checked byChristine Klimanskis, ELS

SEATTLE — In this video, Eleonora M. Lad, MD, PhD, vice chair of ophthalmology clinical research at Duke Health, discusses a presentation at the ARVO meeting on retinal pigment epithelium cells in age-related macular degeneration.

In the presentation, Jason Miller, MD, PhD, discussed the role of retinal pigment epithelium (RPE) cells, which create distinct lipid droplet populations in patients with AMD, Lad said.

“They are hypothesizing that certain drugs can affect different types of lipids to impact disease progression. I thought that was very interesting,” Lad said.

Reference:

Miller JML, et al. Advances in retina/RPE therapeutics: New drugs, mechanisms of action, toxicity, and metabolic insights. Presented at: Association for Research in Vision and Ophthalmology meeting; May 5-9, 2024; Seattle.

Published by:

Sources/Disclosures

Collapse

Source:

Healio Interviews

Disclosures: Lad reports serving as a scientific advisor for 4DMT, Alexion, Allegro, Annexon, Apellis, Aspen Neuroscience, Blue Rock, Boehringer Ingelheim, Broadwing Bio, Complement Therapeutics, Emmecell, Galimedix, IMI-2 Consortium, Iveric Bio/Astellas, Janssen, Kriya Therapeutics, LumiThera, Lutronic Vision, Nanoscope Therapeutics, NGM Biopharmaceuticals, Novartis, Ocular Therapeutix, Osanni Bio, Perceive Bio, Regeneron, Retrotope, Roche, Sanofi and Thea Laboratoires; receiving research funding from Alexion, Apellis, Belite Bio, Boehringer Ingelheim, Gemini Therapeutics, Iveric Bio, Janssen, LumiThera, Neurotech, NGM Biopharmaceuticals, NIH/NEI K23, Novartis, Research to Prevent Blindness, Roche and VA CSR&D I01; owning stock options in Osanni Bio; and having provisional patent 63162741: “A system and method to predict progression of age-related macular degeneration.”

Take Homes in AMD

Read more

VIDEO: Presentation focuses on RPE cells in AMD

Reference:

Related Content